Muñoz-González, F.; Correa-Basurto, J.; Ignacio-Mejia, I.; Bandala, C.
In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors. Curr. Issues Mol. Biol. 2025, 47, 789.
https://doi.org/10.3390/cimb47100789
AMA Style
Muñoz-González F, Correa-Basurto J, Ignacio-Mejia I, Bandala C.
In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors. Current Issues in Molecular Biology. 2025; 47(10):789.
https://doi.org/10.3390/cimb47100789
Chicago/Turabian Style
Muñoz-González, Felipe, José Correa-Basurto, Iván Ignacio-Mejia, and Cindy Bandala.
2025. "In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors" Current Issues in Molecular Biology 47, no. 10: 789.
https://doi.org/10.3390/cimb47100789
APA Style
Muñoz-González, F., Correa-Basurto, J., Ignacio-Mejia, I., & Bandala, C.
(2025). In Silico Multitarget Profiling of Non-Selective Beta-Blockers Highlights Their Potential as Key Agents in Breast Cancer Adjuvant Therapy via ADRB2, ERBB2, and NPYR Receptors. Current Issues in Molecular Biology, 47(10), 789.
https://doi.org/10.3390/cimb47100789